Search research articles
Contact Us
Filters
Showing results (131-140 of 179) with videos related to
Page
of 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2013
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer
Ayca Gucalp, Sara Tolaney, Steven J Isakoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
Lisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Andres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Oncotarget
|
December 29, 2016
Genomic regulation of invasion by STAT3 in triple negative breast cancer
Joy M McDaniel, Katherine E Varley, Jason Gertz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 4, 2008
Hodgkin disease/lymphoma
Richard T Hoppe, Ranjana Hira Advani, Richard F Ambinder, et al.
Blood
|
January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
David J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
Science Translational Medicine
|
March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma
Bart Burington, Peng Yue, Xiaoyan Shi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 16, 2011
Hodgkin lymphoma
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 2, 2006
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology
Andrew D Zelenetz, Ranjana H Advani, Francis Buadi, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 179) with videos related to
Sort By:
Page
of 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2013
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer
Ayca Gucalp, Sara Tolaney, Steven J Isakoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
Lisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Andres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Oncotarget
|
December 29, 2016
Genomic regulation of invasion by STAT3 in triple negative breast cancer
Joy M McDaniel, Katherine E Varley, Jason Gertz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 4, 2008
Hodgkin disease/lymphoma
Richard T Hoppe, Ranjana Hira Advani, Richard F Ambinder, et al.
Blood
|
January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
David J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
Science Translational Medicine
|
March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma
Bart Burington, Peng Yue, Xiaoyan Shi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 16, 2011
Hodgkin lymphoma
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 2, 2006
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology
Andrew D Zelenetz, Ranjana H Advani, Francis Buadi, et al.
Page
of 18